Novavax, Inc. (NASDAQ:NVAX) ranks among the most oversold biotech stocks to invest in. Novavax, Inc. (NASDAQ:NVAX) announced its third-quarter 2025 financial results on November 6, emphasizing the company’s continuous strategic shift from a direct COVID-19 commercial operation to an R&D-focused company, especially in partnership with Sanofi. For the third quarter, Novavax, Inc. (NASDAQ:NVAX) reported total revenue of $70 million, an 18$85 million during the same period the previous year. Mean ...